StockData

Hyperfine vs Nano-X Imaging

HYPR and NNOX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HYPR and NNOX compare

Hyperfine grew revenue faster over the last twelve months (53.2% versus 15.4% for Nano-X Imaging).

Hyperfine keeps more of each dollar of sales as profit, with a net margin of −211% compared with −576% at Nano-X Imaging.

Hyperfine scores higher on the StockData Score (9 against 5 for Nano-X Imaging), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHYPRNNOX
Size and price
Market cap$59.6M–
Share price$0.562$0.287
Change, 1 year−51.2%−90.3%
Change, 5 years−94.3%−98.6%
Beta (5Y)1.253.49
Employees102197
StockData Score
Total score9 (better)5
Valuation score3 (better)0
Growth score3 (better)2
Performance score11
Health score22
Dividend score00
Valuation
P/S3.6×–
P/B1.6×–
FCF yield−46.2%–
Fair value$0.778–
Margin of safety27.8%–
Growth
Revenue growth (TTM)53.2% (better)15.4%
Revenue growth, 5Y average115%–
Profitability
Gross margin51.4% (better)−98.2%
Operating margin−203% (better)−601%
Net margin−211% (better)−576%
FCF margin−166% (better)−346%
Return on equity−97.0%−63.6% (better)
Return on invested capital−327%−59.5% (better)
Financial health
Debt / equity0.360.04 (better)
Current ratio6.15 (better)2.84
Altman Z-score−6.92–
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions20.6%13.9%
Held by insiders18.1%10.4%
Insider net buying, 12 months−$91.9K$190K (better)
Short interest, % of float4.5%9.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.